Long-term solutions needed for kidney disease, says EAF report

29 January 2015

Greater education and support for non-specialist health care professionals is needed to ensure the accurate diagnosis of autosomal dominant polycystic kidney disease (ADPKD), a chronic, progressive, inherited disease in which fluid-filled cysts grow in the kidneys and liver, according to a new report released today.

The European ADPKD Forum (EAF), an international, multidisciplinary panel of experts from the fields of nephrology, hepatology and genetics, has produced the report titled, Translating Science into Policy to Improve ADPKD Care in Europe. It details the role of health care professionals to improve the development and delivery of ADPKD care, and provides an overview of the current management of ADPKD throughout Europe.

Variation in standards

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK